CN104644759B - A kind of health protection tea for preventing or/and treating influenza and preparation method thereof - Google Patents
A kind of health protection tea for preventing or/and treating influenza and preparation method thereof Download PDFInfo
- Publication number
- CN104644759B CN104644759B CN201410613353.9A CN201410613353A CN104644759B CN 104644759 B CN104644759 B CN 104644759B CN 201410613353 A CN201410613353 A CN 201410613353A CN 104644759 B CN104644759 B CN 104644759B
- Authority
- CN
- China
- Prior art keywords
- ginseng
- honeysuckle
- influenza
- health protection
- protection tea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010022000 influenza Diseases 0.000 title claims abstract description 73
- 230000036541 health Effects 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 241001122767 Theaceae Species 0.000 title description 53
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 54
- 241000208340 Araliaceae Species 0.000 claims abstract description 48
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 46
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 46
- 235000008434 ginseng Nutrition 0.000 claims abstract description 46
- 241000555712 Forsythia Species 0.000 claims abstract description 29
- 244000269722 Thea sinensis Species 0.000 claims abstract 8
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract 6
- 239000003814 drug Substances 0.000 claims description 58
- 239000000284 extract Substances 0.000 claims description 41
- 238000000605 extraction Methods 0.000 claims description 40
- 229940079593 drug Drugs 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 238000001035 drying Methods 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 25
- 238000010438 heat treatment Methods 0.000 claims description 23
- 238000012545 processing Methods 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 230000001476 alcoholic effect Effects 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 229910052737 gold Inorganic materials 0.000 claims description 4
- 239000010931 gold Substances 0.000 claims description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 30
- 230000002265 prevention Effects 0.000 abstract description 8
- 239000002304 perfume Substances 0.000 abstract description 3
- 230000008092 positive effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 71
- 235000013616 tea Nutrition 0.000 description 58
- 241001570521 Lonicera periclymenum Species 0.000 description 52
- 239000002775 capsule Substances 0.000 description 41
- 210000004072 lung Anatomy 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 29
- 241000576429 Forsythia suspensa Species 0.000 description 28
- 241000700605 Viruses Species 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- -1 glucose Glucoside Chemical class 0.000 description 10
- 229930182478 glucoside Natural products 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 229920001231 Polysaccharide peptide Polymers 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 108010022457 polysaccharide peptide Proteins 0.000 description 8
- 229960000329 ribavirin Drugs 0.000 description 8
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 231100000816 toxic dose Toxicity 0.000 description 8
- 241000712461 unidentified influenza virus Species 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000012449 Kunming mouse Methods 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 150000008131 glucosides Chemical class 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 230000000242 pagocytic effect Effects 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 5
- 206010010144 Completed suicide Diseases 0.000 description 5
- 206010057249 Phagocytosis Diseases 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 5
- 230000035931 haemagglutination Effects 0.000 description 5
- 238000007654 immersion Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000008782 phagocytosis Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000008719 thickening Effects 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 240000002853 Nelumbo nucifera Species 0.000 description 4
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 4
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229930182494 ginsenoside Natural products 0.000 description 4
- 229940089161 ginsenoside Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940126678 chinese medicines Drugs 0.000 description 3
- 229940074393 chlorogenic acid Drugs 0.000 description 3
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 3
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 3
- 235000001368 chlorogenic acid Nutrition 0.000 description 3
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 3
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 231100000028 nontoxic concentration Toxicity 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 2
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000208828 Caprifoliaceae Species 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000207834 Oleaceae Species 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 241000607764 Shigella dysenteriae Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000000496 cardiotonic agent Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 229940007046 shigella dysenteriae Drugs 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- UGJAEDFOKNAMQD-DVQDXYAYSA-N (-)-Falcarinol Natural products CCCCCCC\C=C\CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-DVQDXYAYSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical group NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- ZHAURGPSJHBQEI-GNFSWKDMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO ZHAURGPSJHBQEI-GNFSWKDMSA-N 0.000 description 1
- UGJAEDFOKNAMQD-MQNTZWLQSA-N (3S,9Z)-1,9-Heptadecadiene-4,6-diyn-3-ol Chemical compound CCCCCCC\C=C/CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-MQNTZWLQSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- UWSONZCNXUSTKW-UHFFFAOYSA-N 4,5-Dimethylthiazole Chemical compound CC=1N=CSC=1C UWSONZCNXUSTKW-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 239000001689 FEMA 4674 Substances 0.000 description 1
- UGJAEDFOKNAMQD-UHFFFAOYSA-N Falcarinol Natural products CCCCCCCC=CCC#CC#CC(O)C=C UGJAEDFOKNAMQD-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 1
- 241001170080 Lonicera hypoglauca Species 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- XYXONTIQGZKCNH-UYKXVWJOSA-N Lonicerin Natural products CO[C@@H]1O[C@@H](O)[C@H]([C@H]2C[C@H](O)[C@H](C)[C@@H]12)C(=O)OC XYXONTIQGZKCNH-UYKXVWJOSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- GXGXUGKOSZFXNS-UHFFFAOYSA-N O-Acetylisobauerenol Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C1(C)CCC1(C)CCC(C)C(C)C12 GXGXUGKOSZFXNS-UHFFFAOYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- SKPPEIDJGJGRGK-UHFFFAOYSA-N Panacen Natural products CCC1=CC=CC2=C1C1OC(C=C=CBr)CC1O2 SKPPEIDJGJGRGK-UHFFFAOYSA-N 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 description 1
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- JJVGFDTWFVSBIM-UHFFFAOYSA-N Phillyrin Natural products COc1ccc(cc1OC)C2OCC3C2COC3c4ccc(OC)c(OC5OC(CO)C(O)C(O)C5O)c4 JJVGFDTWFVSBIM-UHFFFAOYSA-N 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 241001128140 Reseda Species 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Chemical class OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical class C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 241000742376 Swertia patens Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229930182647 Trilobatin Natural products 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- SHPPXMGVUDNKLV-UHFFFAOYSA-N Veronicastroside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 SHPPXMGVUDNKLV-UHFFFAOYSA-N 0.000 description 1
- GXGXUGKOSZFXNS-AULXUAOGSA-N [(3s,4ar,6as,6bs,8ar,11r,12s,12ar,14bs)-4,4,6a,6b,8a,11,12,14b-octamethyl-2,3,4a,5,6,7,8,9,10,11,12,12a,13,14-tetradecahydro-1h-picen-3-yl] acetate Chemical compound C([C@@]12C)C[C@H](OC(C)=O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@]1(C)CC[C@@]1(C)CC[C@@H](C)[C@H](C)[C@H]12 GXGXUGKOSZFXNS-AULXUAOGSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 1
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- SHPPXMGVUDNKLV-KMFFXDMSSA-N luteolin 7-O-neohesperidoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 SHPPXMGVUDNKLV-KMFFXDMSSA-N 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 235000015091 medicinal tea Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229930182783 neolignan Natural products 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- KKAHGGJBKUXDNQ-KRWDZBQOSA-N panaxynol Natural products CCCCCCCC=CC=CCC#C[C@@H](O)C=C KKAHGGJBKUXDNQ-KRWDZBQOSA-N 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- DJHDOMQWAUJNKX-UHFFFAOYSA-N phillygenin Natural products COc1ccc(cc1O)C2OCC3C2COC3c4ccc(OC)c(OC)c4 DJHDOMQWAUJNKX-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- CPJKKWDCUOOTEW-UHFFFAOYSA-N sylvatesmin Natural products C1=C(OC)C(OC)=CC=C1C1C(COC2C=3C=C(OC)C(O)=CC=3)C2CO1 CPJKKWDCUOOTEW-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- GSTCPEBQYSOEHV-QNDFHXLGSA-N trilobatin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 GSTCPEBQYSOEHV-QNDFHXLGSA-N 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
- 239000008782 xin-kang Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of health protection tea for preventing or/and treating influenza and preparation method thereof, the health protection tea is made up of the honeysuckle in soak ginseng extract solution, Folium Forsythia.Honeysuckle, cold and ginseng the dry property of Folium Forsythia are mutually balanced or offset in the preventing and treating influenza health protection tea of the present invention, tea perfume is mellow, warm without cold, not dry, immunocompetence health tea use can either be strengthened in enough be used as in influenza suffering season for the treatment of influenza and can, suitable for the daily tea-drinking of people, play a part of prevention well, treatment influenza.It is the positive effect of this health protection tea, convenient to take, in good taste, it is without any side effects.
Description
Technical field
It is more particularly to a kind of the present invention relates to a kind of health products for preventing or/and treating influenza and preparation method thereof
Health protection tea of prevention or treatment influenza from plant and preparation method thereof, belongs to medicinal tea, drink and functional food field.
Background technology
Honeysuckle, scientific name (Japan-ese Honeysuckle), also known as honeysuckle, it is that Caprifoliaceae perennial half is evergreen woody
Plant." honeysuckle " one is come from《Compendium of Materia Medica》, because honeysuckle flowers are just opened as white, after switch to yellow, hence obtain one's name gold and silver
Flower.Medicinal material honeysuckle is for Caprifoliaceae woodbine honeysuckle and congener dry flower or with the flower just opened.Honeysuckle is from ancient times
It is described as clearing heat and detoxicating good medicine.The sweet cold air fragrance of its property, for clear heat with drugs of sweet flavour and cold nature without injuring one's stomach, fragrance reaches thoroughly again can eliminating evil.Honeysuckle
Can dispelling wind-heat, also kind removing summer-heat blood poison, for various febrile diseases, such as body heat, dermexanthesis, send out spot, heat toxin sore carbuncle, abscess of throat
Disease, equal significant effect.Honeysuckle contains material largely beneficial to human body, including chlorogenic acid, isochlorogenic acid, reseda
Acid, cyanidenon-glucoside, lonicerin, saponin(e, volatile oil, inositol, tannin, iridoid glycoside driffractive ring loganin, Swertia patens
Glucoside etc., belong to rare traditional Chinese medicine, Yimeng Mountain area is the main place of production.
Honeysuckle is just extensive and famous with its medical value since ancient times.《Sheng Nong's herbal classic》Carry：" honeysuckle taste cold in nature
It is sweet, there is the effect of clearing heat and detoxicating, cool bloodization is become silted up, cure mainly affection of exogenous wind-heat, seasonal febrile diseases from the beginning of, sore serious case of furuncle, red and swollen heat pain, just purulence
Blood " etc..《Compendium of Materia Medica》In honeysuckle has been discussed in detail there is the effect of " long term usage is made light of one's life by commiting suicide, promoted longevity ".Twentieth century 80
Age, health ministry have successively carried out chemical analysis to honeysuckle, the results showed that：It is necessary micro- that honeysuckle contains a variety of human bodies
Secondary element and chemical composition, simultaneously containing a variety of active enzyme materials favourable to human body, there is anti-aging, anti-canceration, make light of one's life by commiting suicide strong
The good effects of body.
The drying blade of the Folium Forsythia category Oleaceae plants capsule of weeping forsythia, according to《Sichuan Province's Chinese medicine standard》Harvesting, and according to《Four
River province prepared slices of Chinese crude drugs concocted specification》Processing.
According to《Compendium of Materia Medica》、《Dictionary of medicinal plant》、《Sheng Nong's herbal classic》Record, capsule of weeping forsythia stem, leaf are produced in SiChuan can control the heart
Lung accumulated heat, clearing away summerheat, promote the production of body fluid to quench thirst, relieving sore-throat wets one's whistle, long-term use makes us that face is pleased, improving eyesight clears away heart-fire, it is resistance to old to make light of one's life by commiting suicide, and makes us shining
Send out youthful vigor.
Ginseng is Araliaceae herbaceos perennial, the Chinese ancient pharmacy ancient books and records on Chinese medicine《Sheng Nong's herbal classic》
Ginseng is classified as top grade, says that " main tonifying five zang organs, soothe the nerves, determine soul, stop palpitate with fear, improving eyesight, happy intelligence development, and long term usage is made light of one's life by commiting suicide macrobiosis for it
The effect of ".Show through modern medicine study and assay, contain a kind of chemical substance for being panaxoside in ginseng, it is right
Adjusting the central nervous system of people, cardiac stimulant, antifatigue, Auto-regulator metabolism etc. has obvious effect, so to treating nervous system
A variety of diseases of cardiovascular system, internal system and reproductive system have good therapeutic action.
Ginseng extract immersion honeysuckle, Folium Forsythia, can make cold, dry property offset, temperature is without cold, not hot-tempered, three kinds of Chinese medicines
It is common play it is anti-cure cold, constitutional effect.
The content of the invention
The main object of the present invention is the health products and Chinese medicine preparation for above-mentioned prevention or/and treatment influenza
The problem of prior art and product are present, there is provided a kind of to be used to prevent or/and treat health protection tea of influenza and preparation method thereof.This
The health protection tea of the preventing and treating influenza of invention, which has, improves human immunological competence, prevention, treats the effect of influenza notable, honeysuckle, company
The dry property for sticking up the cold and ginseng of leaf is mutually balanced or offset, and tea perfume is mellow, warm without cold, not dry, suitable for the daily tea of people
Drink.And the prevention of the present invention or/and treat the preparation method simplicity of health protection tea of influenza, stable processing technique, cheap
It is and easy to carry and use
To realize the purpose of the present invention, one aspect of the present invention provides a kind of health care for preventing or/and treating influenza
Tea, including the following raw material：Honeysuckle, the capsule of weeping forsythia, ginseng.
Wherein, the weight of the raw material is：Honeysuckle：Folium Forsythia：Ginseng is 100：100：1-10, it is preferably
100：100：2-5.
Particularly, the capsule of weeping forsythia selection Folium Forsythia；Ginseng selection ginseng stem, folium panacis japonici cum caule or one kind in ginseng or
It is a variety of.
Honeysuckle, Folium Forsythia, ginseng are applied in combination in the health protection tea of the preventing and treating influenza of the present invention so that the effect of each medicine
Synergistic function is produced, improves prevention, the efficiency for the treatment of influenza.
Honeysuckle nickname honeysuckle flower, honeysuckle, two flowers, two precious flowers, are caprifoliaceae plant honeysuckle, lonicera hypoglauca miq, Honeysuckle flower (hair calyx
Honeysuckle) or hair style honeysuckle dry flower or with the flower just opened.It is cold in nature, sweet；Return lung, the heart, stomach.With clearing heat and detoxicating,
The effect of wind-heat dissipating, it is mainly used in carbuncle swells furunculosis, larynx numbness, erysipelas, toxic-heat and blood stasis, anemopyretic cold, warm disease heating.
Honeysuckle be used for affection of exogenous wind-heat or warm disease from the beginning of；Sore and toxic, abscess of throat；Rush down dysentery caused by heat toxin is had blood in stool (excrement
Just mucus and blood are accompanied in).Both can clear thin table, and can solution noxious heat in the blood system, particularly control the key medicine of positive sore.
The chemical composition of honeysuckle mainly contains cyanidenon, chlorogenic acid, isochlorogenic acid, gingko alcohol, cupreol, beans steroid
Alcohol, cupreol-D-Glucose glucoside, stigmasterol-D-Glucose glucoside etc., inositol about 1% and saponin, tannin etc..
Modern pharmacological research shows that honeysuckle acts on 1. resisting pathogenic microbes：Experiment in vitro shows a variety of causes of honeysuckle
Germ such as staphylococcus aureus, hemolytic streptococcus, Escherichia coli, shigella dysenteriae, comma bacillus, typhoid bacillus, paratyphoid
Bacillus etc. has certain inhibitory action, also effective to pneumococcus, diplococcus meningitidis, Pseudomonas aeruginosa, tubercle bacillus.Flooding agent
Stronger than decoction effect, leaf decoction is stronger than the effect of colored decoction.2. anti-inflammatory and refrigeration function：Flos Lonicerae extractive solution 0.25g/ is injected intraperitoneally
Kg, Rat Carrageenan colloidality pin can be suppressed and swollen.3. the function that strengthens the defense acts on：Honeysuckle decoction is diluted to 1：1280 concentration,
Remain to promote the phagocytic function of leucocyte.Mouse peritoneal injection honeysuckle flower injection, also it is obviously promoted inflammatory cell phagocytosis work(
The effect of energy.4. central excitation acts on：After the kinds of experiments such as electroconvulsive shock, rotating cage method proves oral chlorogenic acid, it can cause big
The animal central nervous systems such as mouse, mouse are excited, and its action intensity is the 1/6 of caffeine.5. effect for reducing blood fat：Rat oral gavage gold
Honeysuckle flower 2.5g/kg can reduce enteral cholesterol absorption, reduce cholesterol level in blood plasma.
The capsule of weeping forsythia also known as connects shell, chrysanthemum bar, yellow chain flower, Huang Qidan, green grass or young crops and sticks up, falls to stick up, and is the drying of the Oleaceae plants capsule of weeping forsythia
Fruit.Cold nature, bitter, return lung, the heart, small intestinl channel.With clearing heat and detoxicating, the function of dispersing swelling and dissipating binds, it is mainly used in treating ulcer,
Scrofula, acute mastitis, erysipelas, anemopyretic cold, warm disease is from the beginning of warm is joined the army, hyperpyrexia polydipsia, coma hair spot, heat gonorrhea renal shutdown.The capsule of weeping forsythia is cool in nature
Bitter, it is light clear to float, all heat of the part of the body cavity above the diaphragm housing the heart and lungs can be controlled, especially can removing toxicity for eliminating carbuncles and dissipating bind.
Capsule of weeping forsythia fruit contains Neolignans：Phillyrin, phillygenin, dextrorotation pinoresinol, dextrorotation rosin spirit glucose
Glucoside；Flavone compound：Rutin；Vinylbenzene analog derivative：The capsule of weeping forsythia fat glucoside A, C, D, E, capsule of weeping forsythia kind glucoside, salidroside；Ethyl ring
Hexanol analog derivative：(wood comes) wooden glucoside, capsule of weeping forsythia cyclohexanol, different capsule of weeping forsythia cyclohexanol, capsule of weeping forsythia cyclohexanol thing, capsule of weeping forsythia cyclohexanol
Ketone, the capsule of weeping forsythia cyclohexanol glucoside A, B, C；Triterpene compound：White firelight or sunlight resin acid, oleanolic acid, ursolic acid, β-amyrin acetic acid esters,
Isobauerenyl Acetate, 20 (S)-Da Ma -24- alkene -3 β, 20- glycol -3- acetic acid esters etc..The blue or green capsule of weeping forsythia contains saponin 4.89%,
Alkaloid 0.2%.
The capsule of weeping forsythia has 1. antibacterial, antivirus action：Weeping forsythia concentrated decoction has antibacterial action in vitro, can suppress typhoid fever bar
Bacterium, paratyphosum Bacterium, Escherichia coli, shigella dysenteriae, corynebacterium diphtheriae and comma bacillus, staphylococcus, streptococcus etc.；Forsythia Suspensa Seeds
Volatilization oil emu has significant antivirus action outside chicken embryo to the 68-1 strains of capital section and celestial platform strain virus.2. the capsule of weeping forsythia is to angiocarpy
System has an impact, and has cardiac stimulant and boosting；3. the capillary permeability caused by capsule of weeping forsythia parenteral solution Dichlorodiphenyl Acetate has obvious suppression
Make and use.4. the capsule of weeping forsythia has inhibitory action to guinea pig in vitro small intestine；5. suppress the effect of elastin laminin enzyme activity；6. Antiradiation injury.
Capsule of weeping forsythia methanolic extract 1g/kg is injected intraperitoneally, and is administered within 5 minutes before roentgen radiation x, has protective action to mouse skin infringement.
Ginseng is Araliaceae herbaceos perennial, the Chinese ancient pharmacy ancient books and records on Chinese medicine《Sheng Nong's herbal classic》
Ginseng is classified as top grade, says that " main tonifying five zang organs, soothe the nerves, determine soul, stop palpitate with fear, improving eyesight, happy intelligence development, and long term usage is made light of one's life by commiting suicide macrobiosis for it
The effect of ".Ginseng is mild-natured, sweet, slight bitter；Returns spleen, lung, the heart channel of Hang-Shaoyin.With reinforcing vital energy, veins takes off admittedly, reinforce the spleen to benefit the lung, promote the production of body fluid,
The function of calming the nerves.Be mainly used in it is physically weak to be taken off, cold weak pulse of limb, spleen eating less, the deficiency syndrome of the lung breathes with cough, injury thirst, Heat Diabetes, prolonged illness
Empty thin, insomnia of palpitating with fear, impotence Gong Leng；Heart failure, cardiogenic shock.
Ginseng contains ginsenoside and a small amount of volatile oil, and Main Ingredients and Appearance is panacene in oil；Isolated according to reports from root
Soaping agents：Panaxoside A, B, C, D, E and F etc..It is first that Panaxatriol ginsenoside is produced after Ginsenoside B and C hydrolysis, panaxoside D,
20- tables ginseng diol saponin member is obtained after E and F hydrolysis.Again beta-elemene is partially separated out from the low boiling of ether extract.It is high
Boiling portion isolates Panaxynol.In addition monosaccharide is still contained：Glucose, fructose, sugarcane candy, three kinds of trisaccharides：Glucose-fruit
Sugar-fructose, three polydextroses, glucose-glucose-fructose, panax acid is (for palmitic acid, stearic acid and linoleic mixing
Thing), more clock vitamin (B1、B2, Yan acid, nicotinic acid amide, pantothenic acid), several amino acids, choline, enzyme (maltose, invertase, ester
Enzyme), spermine and cholamine.The aerial part of ginseng contains flavone compound, and people claims ginseng Huang glucoside, trilobatin, kaempferol, ginseng soap
Glucoside, cupreol and carbohydrate.
The main composition of ginseng is panaxoside (Ginsenoside), and modern pharmacological research proves that it has and improved
Immune, strengthening by means of tonics, promoting blood circulation and removing blood stasis, antifatigue and other effects.
Another aspect of the present invention provides a kind of preparation method for the health protection tea for preventing or/and treating influenza, including
Following steps：
1) bulk drug is prepared according to following weight：
Honeysuckle 100, the capsule of weeping forsythia 100, ginseng 1-10
2) people is participated in carrying out heating extraction after Extraction solvent mixes, collects extract solution；
3) extract solution is concentrated, ginseng extract medicinal extract is made；
4) ginseng extract medicinal extract is well mixed with water or alcoholic solution, ginseng extract solution is made；
5) honeysuckle, the capsule of weeping forsythia are well mixed with ginseng extract solution, honeysuckle-capsule of weeping forsythia-ginseng mixture are made, so
After carry out drying and processing, produce.
Wherein, the weight of bulk drug described in step 1) is：Honeysuckle 100, the capsule of weeping forsythia 100, ginseng 2-5.
Particularly, the capsule of weeping forsythia selection Folium Forsythia；Ginseng selection ginseng stem, folium panacis japonici cum caule or one kind in ginseng or
It is a variety of.
Wherein, the selection water of Extraction solvent described in step 2) or alcoholic solution.
Particularly, the alcoholic solution selection mass percent concentration is molten for 1-80% ethanol-water solution or methanol-water
Liquid, preferably mass percent concentration are 10-60% ethanol-water solutions or methanol-water solution.
Wherein, Extracting temperature is 85-100 DEG C, preferably 90-100 DEG C during the heating extraction；Extraction time is 2-
3 times；Each extraction time is 30-90min.
Particularly, the weight that people participates in Extraction solvent during each heating extraction is 8-12：1.
Particularly, after in addition to people being participated in into Extraction solvent mixing, described heating extraction is being carried out after soaking 30-60min.
Wherein, described heating extraction includes the step of order below is carried out：
A) ginseng is added in Extraction solvent, the Extraction solvent of addition and the weight ratio of ginseng are 8-12：
1, first time heating extraction is carried out after soaking 30-60min, heating-up temperature is 85-100 DEG C, and the heating extraction time is
30-90min；
B) first time extract solution is filtered, collects filtrate；
C Extraction solvent) is added into filter residue 1-2 times, carries out heating extraction, wherein, the weight of the Extraction solvent added every time
Amount and the weight ratio of ginseng are 8-12：1, heating-up temperature is 85-100 DEG C, and the heating extraction time is 30-90min；
D) filter, the filtrate after filtering is merged, obtains Ginseng extract.
Wherein, the relative density of ginseng extract medicinal extract described in step 3) is 1.05-1.25, i.e., Ginseng extract is dense
It is 1.05-1.25 to be reduced to relative density；Thickening temperature is 80-90 DEG C in the concentration process.
Wherein, alcoholic solution described in step 4) selects the ethanol solution-aqueous solution of the mass percent concentration for 30-50%；
The wet concentration selects the hot water that temperature is 50-70 DEG C, preferably 60 DEG C of hot water.Ginseng extract medicinal extract mixes with water or alcoholic solution
Afterwards, dissolve, ginseng extract solution is made.
Particularly, the weight of the ginseng extract medicinal extract and water or alcoholic solution is 1-60：100, preferably 10-
50：100.
Wherein, the concentration of ginseng extract solution described in step 4) is 1-60% (w/v), preferably 10-50% (w/v).
Wherein, in step 5) also include will be well mixed honeysuckle with the ginseng extract solution, the capsule of weeping forsythia is immersed in institute
Carry out described drying and processing in the ginseng extract solution stated after 30-60min again.
Particularly, the temperature of the immersion is 30-50 DEG C.
Wherein, the temperature of drying and processing described in step 5) is 60-90 DEG C.
Particularly, in addition to the mixture after drying is crushed and crosses 10 mesh sieves.
The active component of the preventing and treating influenza health protection tea of the present invention can add various routines required when preparing different dosage forms
Auxiliary material, such as disintegrant, lubricant, binder are prepared into any conventional oral agents with the method for Chinese medicinal of routine
Type, such as pill, powder, tablet, granule, capsule, oral liquid.
Health protection tea of the present invention has dispelling wind-heat, and removing summer-heat blood poison is thoroughly evil outgoing, mass dissipating and swelling eliminating, goes the functions such as remove pathogenic factor, uses
In prevention, treatment influenza.
Preventing and treating influenza health protection tea prepared by the present invention is in use, oral 2-3 times daily, each 2-5 grams (crude drug), Ke Yizuo
It is used continuously for daily drinks, strengthens immunity of organisms, prevention, treatment influenza..
The health protection tea of the preventing and treating influenza of the present invention has the following advantages that and benefit：
1st, the health protection tea prescription compatibility science of preventing and treating influenza of the invention, it is curative for effect, it is safe, it is quality controllable.
2nd, in the health protection tea of preventing and treating influenza of the invention honeysuckle, cold and ginseng the dry property of Folium Forsythia mutually balance or
Offset, tea perfume is mellow, warm without cold, not dry, suitable for the daily tea-drinking of people.
3rd, the present invention prepares honeysuckle during the health protection tea for preventing and treating influenza, and Folium Forsythia is soaked in ginseng extract solution
In after, directly dry with ginseng extract, without extraction, without the loss of any composition, farthest remain in the lump
The active ingredient of medicine, give full play to the effect of its anti influenza.
4th, the invention provides a kind of new honeysuckle, the application form of Folium Forsythia.
5th, the health protection tea of preventing and treating influenza prepared by the present invention, is rationally compounded using crude drug and formed, and people is adjusted from ginseng
Body immunity is set about, and by honeysuckle, the two classical clearing heat and detoxicating traditional Chinese medicine collective effects of Folium Forsythia, reaches pre-
Anti-, treatment influenza purpose, therefore, product of the invention has the multi-efficiency for influenza for the treatment of both principal and secondary aspect of disease, prevent and treat.
6th, the preparation method of the health protection tea of preventing and treating influenza of the invention is simple, and process conditions are gentle, and manufacturing cost is low.
Embodiment
The invention will now be further described with reference to specific embodiments, advantages of the present invention and feature will be with description and
It is apparent.But these embodiments are only exemplary, do not form any restrictions to the scope of the present invention.People in the art
Member to the details and form of technical solution of the present invention it should be understood that can enter without departing from the spirit and scope of the invention
Row modifications or substitutions, but these modifications and replacement are each fallen within protection scope of the present invention.
Embodiment 1
1st, (× 100g) is stocked up according to following weight proportion
The gen-seng haulms 5 of 100 Folium Forsythia of honeysuckle 100
2nd, ginseng extract medicinal extract is prepared
2-1) raw medicinal material gen-seng haulms 500g and running water are added in Multifunctional Chinese medicine extractor, in room temperature (15-
30 DEG C) under soak 30min, wherein the weight ratio of running water and gen-seng haulms is 12：1；
2-2) open multi-function extractor power supply to be heated, be heated to 100 DEG C, keep constant temperature extraction at this temperature
60min, then filter, obtain first time extract solution；
2-3) point 2 addition running water into filter residue, heating extraction 2 times, the temperature of each heating extraction is 100 DEG C, is added
The weight of the running water entered is 12 with gen-seng haulms weight ratio：1, extraction time is 1 hour, is filtrated to get No. 2 extract solutions；
2-4) extract solution of 3 heating is merged, is heated after obtaining total extract solution, is evaporated concentration, obtained
To the medicinal extract (162g) that relative density is 1.1, wherein, thickening temperature is 90 DEG C；
3rd, ginseng extract solution is prepared
It is 60 DEG C of hot water to add temperature in the ginseng extract medicinal extract prepared to step 2), stirring, is uniformly dissolved, people is made
Conopsea extraction solution (540ml), the wherein concentration of ginseng extract solution are 30% (w/v)；
4th, honeysuckle-capsule of weeping forsythia-ginseng mixture is prepared
Honeysuckle, Folium Forsythia are mixed with ginseng extract solution, and soaked with ginseng extract solution, stirring
It is even, obtain honeysuckle-capsule of weeping forsythia-ginseng mixture after soaking 60min at 30 DEG C；Honeysuckle, Folium Forsythia will in immersion process
Ginseng extract solution all absorbs.
5th, drying and processing
Honeysuckle-capsule of weeping forsythia-ginseng mixture of acquisition is placed in baking oven, carries out normal pressure drying and processing, wherein drying temperature
Spend for 90 DEG C, be dried to moisture content as 12%；
Mixture after drying is crushed and packed after crossing 10 mesh sieves, the health protection teas of 100,000 bags of preventing and treating influenzas are made.
Embodiment 2
1st, (× 100g) is stocked up according to following weight proportion
The gen-seng haulms 3 of 100 Folium Forsythia of honeysuckle 100
2nd, ginseng extract medicinal extract is prepared
2-1) raw medicinal material ginseng 300g and running water are added in Multifunctional Chinese medicine extractor, soak 45min,
Wherein the weight ratio of running water and gen-seng haulms is 10：1；
2-2) open multi-function extractor power supply to be heated, be heated to 90 DEG C, keep constant temperature extraction at this temperature
90min, then filter, obtain first time extract solution；
2-3) point 2 addition running water into filter residue, heating extraction 2 times, the temperature of each heating extraction is 90 DEG C, is added
The weight of the running water entered is 10 with ginseng weight ratio：1, extraction time 90min, it is filtrated to get No. 2 extract solutions；
2-4) extract solution of 3 heating is merged, is heated after obtaining total extract solution, is evaporated concentration, obtained
To the medicinal extract (87g) that relative density is 1.2, wherein, thickening temperature is 80 DEG C；
3rd, ginseng extract solution is prepared
30% ethanol-water solution is added in the ginseng extract medicinal extract prepared to step 2), stirring, is uniformly dissolved, is made
Into ginseng extract solution (174ml), the wherein concentration of ginseng extract solution is 50% (w/v)；
4th, honeysuckle-capsule of weeping forsythia-ginseng mixture is prepared
Honeysuckle, Folium Forsythia are mixed with ginseng extract solution, and soaked with ginseng extract solution, stirring
It is even, obtain honeysuckle-capsule of weeping forsythia-ginseng mixture after soaking 40min at 50 DEG C；Honeysuckle, Folium Forsythia will in immersion process
Ginseng extract solution all absorbs.
5th, drying and processing
Honeysuckle-capsule of weeping forsythia-ginseng mixture of acquisition is placed in baking oven, carries out normal pressure drying and processing, wherein drying temperature
Spend for 80 DEG C, be dried to moisture content as 15%；
Mixture after drying is crushed and packed after crossing 10 mesh sieves, the health protection teas of 100,000 bags of preventing and treating influenzas are made.
Embodiment 3
1st, (× 100g) is stocked up according to following weight proportion
The gen-seng haulms 2 of 100 Folium Forsythia of honeysuckle 100
2nd, ginseng extract medicinal extract is prepared
2-1) raw medicinal material gen-seng haulms 200g and running water are added in Multifunctional Chinese medicine extractor, soaked
60min, wherein running water and gen-seng haulms weight ratio are 8：1；
2-2) open multi-function extractor power supply to be heated, be heated to 100 DEG C, keep constant temperature extraction at this temperature
30min, then filter, obtain first time extract solution；
2-3) point 2 addition running water into filter residue, heating extraction 2 times, the temperature of each heating extraction is 100 DEG C, is added
The weight of the running water entered is 8 with ginseng weight ratio：1, extraction time 30min, it is filtrated to get No. 2 extract solutions；
2-4) extract solution of 3 heating is merged, is heated after obtaining total extract solution, is evaporated concentration, obtained
To the medicinal extract (82g) that relative density is 1.05, wherein, thickening temperature is 85 DEG C；
3rd, ginseng extract solution is prepared
The ethanol-water solution that mass percent concentration is 30% is added in the ginseng extract medicinal extract prepared to step 2),
Stirring, is uniformly dissolved, ginseng extract solution (820ml) is made, the wherein concentration of ginseng extract solution is 10% (w/v)；
4th, honeysuckle-capsule of weeping forsythia-ginseng mixture is prepared
Honeysuckle, Folium Forsythia are mixed with ginseng extract solution, and are soaked in ginseng extract solution, stirring is equal
It is even, obtain honeysuckle-capsule of weeping forsythia-ginseng mixture after soaking 30min at 50 DEG C；Honeysuckle, Folium Forsythia will in immersion process
Ginseng extract solution all absorbs.
5th, drying and processing
Honeysuckle-capsule of weeping forsythia-ginseng mixture of acquisition is placed in baking oven, carries out normal pressure drying and processing, wherein drying temperature
Spend for 85 DEG C, be dried to moisture content as 9%；
Mixture after drying is crushed and packed after crossing 10 mesh sieves, the health protection teas of 100,000 bags of preventing and treating influenzas are made.
Embodiment 4
1st, (× 100g) is stocked up according to following weight proportion
The gen-seng haulms 4 of 100 Folium Forsythia of honeysuckle 100
2nd, ginseng extract medicinal extract is prepared
2-1) raw medicinal material ginseng 400g and running water are added in Multifunctional Chinese medicine extractor, soak 60min,
Wherein the weight ratio of running water and gen-seng haulms is 12：1；
2-2) open multi-function extractor power supply to be heated, be heated to 85 DEG C, keep constant temperature extraction at this temperature
90min, then filter, obtain first time extract solution；
Running water, heating extraction 1 time 2-3) are added into filter residue, heating extraction temperature is 85 DEG C, the running water of addition
Weight is 12 with ginseng weight ratio：1, extraction time 90min, it is filtrated to get No. the 2nd extract solution；
2-4) extract solution of 2 heating is merged, is heated after obtaining total extract solution, is evaporated concentration, obtained
To the medicinal extract (118g) that relative density is 1.1, wherein, thickening temperature is 80 DEG C；
3rd, ginseng extract solution is prepared
The ethanol-water solution that mass percent concentration is 50% is added in the ginseng extract medicinal extract prepared to step 2),
Stirring, is uniformly dissolved, ginseng extract solution (295ml) is made, the wherein concentration of ginseng extract solution is 40% (w/v)；
4th, honeysuckle-capsule of weeping forsythia-ginseng mixture is prepared
Mix, and be soaked in ginseng extract solution by honeysuckle, Folium Forsythia, with ginseng extract solution, stirring is equal
It is even, obtain honeysuckle-capsule of weeping forsythia-ginseng mixture after soaking 50min at 40 DEG C；
5th, drying and processing
Honeysuckle-capsule of weeping forsythia-ginseng mixture of acquisition is placed in baking oven, carries out normal pressure drying and processing, wherein drying temperature
Spend for 70 DEG C, be dried to moisture content as 14%；
Mixture after drying is crushed and packed after crossing 10 mesh sieves, the health protection teas of 100,000 bags of preventing and treating influenzas are made.
Test example 1 prevents and treats the research of influenza health protection tea resisiting influenza virus effect
1. experiment material
1.1 medicine
Prevent and treat influenza health protection tea：Dalian Fu Sheng natural drugs development corporation, Ltd. produces, lot number：20130121.
Ribavirin injection, colourless transparent liquid, produced by Henan Run Hong limited companies, batch number：
1206261, Chinese medicines quasi-word：H19993553,100mg/ml, as this experiment positive control medicine.
Above-mentioned medicine uses dissolved in purified water, and filtration, degerming packing, 4 DEG C standby, for this experiment medicine to be measured.
1.2 cell line
Vero (African green monkey kidney cell cell) preserves cell line by preclinical medicine institute of Jilin University.
1.3 Strain
1) influenza virus is purchased from Inst. of Viruses, China Preventive Medicine Science Academy.
2) parainfluenza virus is purchased from Inst. of Viruses, China Preventive Medicine Science Academy.
3) Respiratory Syncytial Virus(RSV) (RSV) is purchased from Inst. of Viruses, China Preventive Medicine Science Academy.
1.4 instruments and reagent
Culture medium：DMEM, HyClone
Hyclone：HyClone
Trypsase：Gibco
MTT：Sigma
DMSO：Tianjin Bei Lian fine chemicals development corporation, Ltd.
Biohazard Safety Equipment：BHC-1300 II A/B3, AIRTECH
CO2Incubator：MCO-18AIC, SANYO
Inverted microscope：CKX41, OLYMPUS
Electronic analytical balance：AR1140/C, DHAUS
2. experimental method
2.1 cells prepare
Vero passage culture 1-2d, are allowed in blocks, and boundary line is clear, when third dimension and strong diopter, are digested with pancreatin,
Treat that needle point sample aperture occurs in cell face, exhaust digestive juice, access milliliter nutrient solution dispels cell, counted, and (contains 10% with nutrient solution
The DMEM of hyclone) it is diluted to about 5 × 107After individual/L, it is inoculated in 96 well culture plates, treats that cell grows up to individual layer.
2.2 drug toxicities determine
Cell toxicity test：Medicine is carried out with maintaining liquid the DMEM of 2% hyclone (contain) concentration as shown in table 1 dilute
Release, for CTA.
The drug dilution of table 1 is with reference to table (unit：g/L)
The medicine of the good various concentrations of above-mentioned dilution is added dropwise on Vero cell monolayers, per hole 0.2ml, each concentration 6
Individual multiple holes, 6 hole normal controls (Normal group for being not added with medicine) and 6 hole blank controls (nutrient solution) are separately set, put 37 DEG C, 5%
CO2Cultivated in incubator, put inverted microscope observation CPE daily and record.After 72h, the μ L (5mg of MTT solution 20 are added per hole
mL- 1), continue to be incubated 4h, each hole nutrient solution is abandoned in suction, and 100 μ L DMSO are added per hole, vibrates 5min, 492nm measure OD values, meter
Calculate cell survival rate.In SPSS18.0 statistical softwares, cell survival rate is subjected to Probit regression analyses, calculates medicine pair
Maximal non-toxic concentration (the TC of Vero cells0) and half toxic concentration (TC50)。
The influence that 2.3 medicines are acted on pathological changes caused by virus
The culture plate for having covered with cell monolayer is taken, nutrient solution is drawn, with 100TCID50Corresponding virus attack amount inoculation is thin
Born of the same parents, 37 DEG C, 5%CO2Incubator adsorbs 2h, adds each decoction of certain concentration (maximal non-toxic concentration or so), per concentration 6
Multiple holes culture, 200 μ L/ holes.If ribavirin injection is positive drug control group, while sets Normal group and (be not added with virus
Not dosing) and virus control group (add virus but be not added with the control group of medicine), influence of the observation medicine to virus cause CPE.72h
Afterwards, with MTT colorimetric methods, OD values are determined under 492nm wavelength, it is efficient (ER%) to calculate Antiviral Effect.United in SPSS18.0
Count in software with the significant difference between more each Antiviral Effect effective percentage of ANOVA methods.
ER%=(drug-treated group mean OD value-virus control group mean OD value)/(cell controls group mean OD value-
Virus control group mean OD value) × 100%
3. experimental result
3.1 drug toxicity measurement results
Maximal non-toxic concentration (TC of each medicine to Vero cells0), half toxic concentration (TC50) and Antiviral Effect experiment
2 are shown in Table with concentration.Preventing and treating influenza health protection tea is to measure half toxic concentration (TC50), its security is good.
Drug cytotoxicity experimental result (the unit of table 2：g/L)
* preventing and treating influenza health protection tea does not measure half toxic concentration (TC50)
3.2 medicines are to pathological changes caused by virus protective effect result
Preventing and treating influenza health protection tea infected by influenza, parainfluenza virus, Respiratory Syncytial Virus(RSV) have good inhibitory action,
Its resisiting influenza virus, Respiratory Syncytial Virus(RSV) are superior to Ribavirin, its effective percentage and Ribavirin phase to parainfluenza virus
When.Experimental result is shown in Table 3.
The Antiviral Effect of table 3 effective percentage (ER%) statistical form
*P<0.05,**P<0.01
The Antiviral assay in vivo of test example 2.
1 experiment material
1.1 medicines and reagent
Prevent and treat influenza health protection tea：Dalian Fu Sheng natural drugs development corporation, Ltd. produces, lot number：20130121；
Positive control drug：Ribavirin injection, produced by Henan Run Hong limited companies, batch number：
1206261, Chinese medicines quasi-word：H19993553.
1.2 instrument
1.3 animal
Kunming mouse male and female half and half, body weight 15-20g, purchased from Dalian Medical Univ's Experimental Animal Center, experimental animal is permitted
Can the number of card：SCXK (the Liao Dynasty) 2004-0017.
2. experimental method
2.1 animal packet
The kunming mice 240 of four week old is taken, carries out 2 experiments.Mouse 120 is taken, is randomly divided into 12 groups, every group 10
Only, the first six group is respectively：Normal group, virus control group, Ribavirin group, the preventing and treating high, medium and low dosage of influenza health protection tea
Group, for preventing and treating the determination test of influenza health protection tea influenza virus infected Lung Exponent and lung index；After and
Six groups are respectively Normal group, virus control group, Ribavirin group, the preventing and treating high, medium and low dosage group of influenza health protection tea, are used for
Influenza health protection tea is prevented and treated to parainfluenza virus infection mouse Lung Exponent and the determination test of lung index；Separately take mouse 120
Only, 12 groups are randomly divided into, every group 10, after being grouped according to above-mentioned packet mode, for preventing and treating influenza health protection tea infected by influenza
The determination test of infecting mouse and parainfluenza virus infection mouse lung suspension viral hemoagglutination titre.
2.2 infection methods
To in addition to Normal group, other group mouse carry out infection processing, and concrete operations are：In 200~300mL
An absorbent cotton is put into the beaker of size, is subsequently poured into appropriate ether (getting wet absorbent cotton), being equipped with absorbent cotton
Beaker back-off come, mouse is put into and anaesthetized, sees that mouse is on wires, hence it is evident that during in powerless sample, mouse is lain on the back, drip
Nose infects 15LD50Influenza virus or parainfluenza virus 0.03ml/ nostrils, Normal group replace viral suspension with physiological saline.
2.3 medications and dosage
The high, medium and low dosage group of influenza health protection tea and Ribavirin control group are prevented and treated, is started respectively at infection the previous day
Conventional gastric infusion, the preventing and treating high, medium and low dosage of influenza health protection tea is respectively 0.26,0.13,0.065g/kg, Li Bawei
Woods positive drug dosage is 58.5mg/kg, and once a day, successive administration 5d, Normal group and virus control group gavage phase
The physiological saline of same volume.
2.4 observation index
1. Lung Exponent determines
The 5th day after mouse medication, first 8 hours fasting for solids and liquids, eyeball sacrificed by exsanguination animal is plucked after weighing, thoracic cavity is opened and plucks
Go out full lung, surface moisture content is blotted with filter paper with brine twice, electronic balance claims lung weight, based on following equation calculating
Calculate Lung Exponent and lung index：
Lung Exponent=(mouse lung weight/mouse weight) × 100%.
Lung index=(the average Lung Exponent of the average Lung Exponent-experimental group of infection model group)/infection model group is averaged
Lung Exponent × 100%.
2. lung suspension viral hemoagglutination titer determination
The each group mouse lung of the 5th day after treating is taken respectively, and the underlying homogenizer of low temperature is ground into homogenate, and normal saline dilution is
10% lung tissue suspension, centrifuging and taking supernatant, doubling dilution, dripped by 0.2ml/ holes on titer plate, 0.2ml1% is added per hole
Chicken erythrocyte suspension, mix, put room temperature 30min, observe and record Hemagglutination titer.Using erythrocyte agglutination (++) Shi as Final points, with outstanding
Liquid extension rate represents its titre.
3. experimental result and analysis
3.1 Lung Exponents determine
After influenza virus and parainfluenza virus infection mouse, average Lung Exponent result is shown：With the model pair of virus infection
Compare according to group, Normal group, each concentration and preventing influenza health protection tea group, Ribavirin group Lung Exponent substantially reduce (P<0.05),
Preventing and treating influenza health care tea concentration has certain protective role in the range of 0.065~0.26g/kg/d, and Lung Exponent substantially reduces, high
Dosage group curative effect is best, in, low dose group and Ribavirin therapeutic equivalence.Experimental result is shown in Table 4,5.
Table 4 prevents and treats the influence of influenza health protection tea influenza virus infected Lung Exponent and lung index
* represent that # is represented compared with Ribavirin group compared with virus control group
Table 5 prevents and treats influence of the influenza health protection tea to parainfluenza virus infection mouse Lung Exponent and lung index
* represent compared with virus control group
3.2 lung suspension viral hemoagglutination titer determinations
After influenza virus and parainfluenza virus infection mouse, the control group lung tissue virus Hemagglutination titer of virus infection
(InX) it is respectively 33.11 and 32.45, after various concentrations preventing and treating influenza health protection tea is treated 5 days, lung tissue virus Hemagglutination titer is equal
It has been declined that, compared with virus control group, difference has conspicuousness, (P<0.05), middle and high dosage group better efficacy, low dose group
With Ribavirin therapeutic equivalence.Experimental result is shown in Table 6, table 7 respectively.
Table 6 prevents and treats the influence of influenza health protection tea influenza virus infected lung suspension Hemagglutination titer
* represent that # is represented compared with Ribavirin group compared with virus control group
Table 7 prevents and treats influence of the influenza health protection tea to parainfluenza virus infection mouse lung suspension Hemagglutination titer
* represent that # is represented compared with Ribavirin group compared with virus control group
Test example 3 prevents and treats the research that influenza health protection tea improves immunity function
1. test material
1) medicine and reagent
Prevent and treat influenza health protection tea：Dalian Fu Sheng natural drugs development corporation, Ltd. produces, lot number： 20130121；
Positive control drug：Polysaccharide-peptide capsule (manufacturer：Shanghai Xinkang Pharmaceutical Factory, lot number：20110306th, specification：
0.5g/ grains etc.)
Protein hydrolysate：(manufacturer：Guangxi Kangzhe Guangming Pharmaceutical Co., Ltd., lot number：20110208th, specification：10ml*6
Branch/box)
Chicken red blood cell：(manufacturer：South chemical reagent work of Yuhuan county, lot number：20101208th, specification：100ml/ bottles)
MTT (3- (4,5- dimethylthiazole -2) -2,5- diphenyltetrazolium bromide bromides)：(manufacturer Shanghai Suo Laibaosheng
Thing Science and Technology Ltd., lot number 20101105, specification：250mg)
2) knurl source S180 sarcoma model, Lewis lung cancer C57BL/6 mouse models are studied by Shanghai medical industry
The passage of pharmacological room of institute maintains.
3) experimental animal
C57BL/6 mouse, Kunming mouse (male), 18-20 grams of body weight, purchased from Dalian Medical Univ experimental animal
The heart, experimental animal credit number：SCXK (the Liao Dynasty) 2004-0017.
2. experimental method
The Peritoneal Macrophage Phagocytosis experiment of 2.1 pairs of normal Kunming mouses
Male Kunming strain mice 60 is taken, is randomly divided into 5 groups, is respectively：The high, medium and low dosage group of influenza health protection tea is prevented and treated,
Positive controls, negative control group, first four groups every group 10, negative control group is 20；
The high, medium and low dosage group of preventing and treating influenza health protection tea, polysaccharide-peptide group, the equal gastric infusion of negative control group, continuous 10
My god, dosage is as shown in table 8, and negative control group gives isometric pure water；
Only, pneumoretroperitoneum injection is per milli within 24 hours by the protein hydrolysate 1.5ml/ of each group mouse peritoneal injection 0.5% after last dose
Rise 1 × 106Chicken erythrocyte suspension 0.2ml/ only；Eluted after 40 minutes with physiological saline, collect mouse peritoneal liquid；Centrifugation,
Take cell precipitation liquid that smear is made, fixed with methanol, Giemsa staining mounting, counted in 100 macrophages and swallowed with oil mirror
The number of macrophages of chicken red blood cell and the sum for swallowing chicken red blood cell, percentage phagocytosis and phagocytic index are calculated by following equation.
Percentage phagocytosis %=(number of macrophages/100 macrophage that chicken red blood cell is swallowed in 100 macrophages)
× 100%；
Sum/100 macrophage of chicken red blood cell is swallowed in the macrophage of phagocytic index=100.
The NK cell activity assays of 2.2 pairs of lotus Lewis lung cancer C57BL/6 mouse
Take C57BL/6 mouse 60, the Lewis lung cancer suspensions 0.05ml/ of the sterile preparation of toe subcutaneous vaccination only (about 1 ×
106Individual tumour cell)；
Next day is randomly divided into 5 groups, is respectively：The high, medium and low dosage group of influenza health protection tea is prevented and treated, positive controls are negative right
According to group, first four groups every group 10, negative control group is 20；
The high, medium and low dosage group of preventing and treating influenza health protection tea, polysaccharide-peptide group, the equal gastric infusion of negative control group, continuous 10
My god, dosage is as shown in table 9, and negative control group gives isometric pure water；
Next day aseptically takes mouse spleen after last dose, and single splenocyte suspension is made with 100 eye mesh screens, low
Removing red blood cell is oozed, cell suspension is transferred in blake bottle, 37 DEG C of 5%CO2CMC model removes attached cell after 1 hour, meter
Number living cells simultaneously adjusts cell concentration as 3 × 106Individual cell/ml is as effector cell.Target cell takes L929 cultured cell in vitro,
Cellar culture 24 hours, cell concentration is adjusted as 1.5 × 10 using nutrient solution5Individual cell/ml, it is 20: 1 to make effect target cell ratio.
96 well culture plates are taken to be separately added into effector cell and target cell, another laying effect cell and target cell control, in 37 DEG C of 5%CO2Bar
After part culture 4 hours, MTT dyeing liquors are added, digestive juice is added after being further cultured for 2 hours and surveys each hole OD values in next day, based on formula
Calculate NK cytotoxic activities.
NK cytotoxic activities %=[target cell control group OD averages-(experimental group OD averages-effector cell OD averages)]/
Target cell control group OD averages } × 100%
3. experimental result
Phagocytic function of the 3.1 preventing and treating influenza health protection teas to normal Kunming mouse peritoneal macrophage
Compared with negative control group, after various concentrations prevent and treat influenza health protection tea and polysaccharide-peptide medication, it swallows percentage
Rate and phagocytic index are obviously improved, and difference has conspicuousness, (P<0.01), illustrate to prevent and treat influenza health protection tea and polysaccharide-peptide all
There is the phagocytic function for improving normal mouse peritoneal macrophage, middle and high dosage group better efficacy, low dose group and cloud
Sesame glycopeptide group therapeutic equivalence.Experimental result is shown in Table 8 respectively.
Table 8 prevents and treats influence of the influenza health protection tea to normal Kunming mouse Peritoneal Macrophage Phagocytosis
The * * * P compared with negative control group<0.01
The NK cell activity assays of 3.2 pairs of lotus Lewis lung cancer C57BL/6 mouse
Compared with negative control group, after various concentrations prevent and treat influenza health protection tea and polysaccharide-peptide medication, its NK cell is lived
Property is obviously improved, and difference has conspicuousness, (P<0.01), illustrate that preventing and treating influenza health protection tea and polysaccharide-peptide all has raising lotus
The effect of the NK cytoactives of Lewis lung cancer C57BL/6 mouse, preventing and treating influenza health protection tea group curative effect are better than polysaccharide-peptide group.It is real
Test result and be shown in Table 9 respectively.
Table 9 prevents and treats influence of the influenza health protection tea to lotus Lewis lung cancer in mice NK activity
1 compared with negative control group * * * P<0.01；
2# refers to the OD values of (effector cell+target cell)-effector cell.
Claims (8)
- A kind of 1. health protection tea for preventing or/and treating influenza, it is characterized in that being prepared by the following raw material medicine：Gold and silver Flower, Folium Forsythia, ginseng, wherein, the bulk drug honeysuckle, Folium Forsythia, the weight of ginseng are 100：100：1-10, institute State one or more of the ginseng in ginseng stem, folium panacis japonici cum caule or ginseng.
- A kind of 2. preparation method for the health protection tea for preventing or/and treating influenza, it is characterized in that comprising the following steps：1) bulk drug is prepared according to following weight：Honeysuckle 100, Folium Forsythia 100, ginseng 1-10Wherein, one or more of the ginseng in ginseng stem, folium panacis japonici cum caule or ginseng；2) people is participated in carrying out heating extraction after Extraction solvent mixes, collects extract solution；3) extract solution is concentrated, ginseng extract medicinal extract is made；4) ginseng extract medicinal extract is well mixed with water or alcoholic solution, ginseng extract solution is made；5) honeysuckle, Folium Forsythia are added in ginseng extract solution, stirring, are well mixed, obtained honeysuckle-Folium Forsythia- Ginseng mixture, drying and processing is then carried out, is produced.
- 3. preparation method as claimed in claim 2, it is characterized in that the weight of bulk drug described in step 1) is：Gold and silver Spend 100, Folium Forsythia 100, ginseng 2-5.
- 4. preparation method as claimed in claim 2 or claim 3, it is characterized in that the selection water of Extraction solvent described in step 2) or alcohol are molten Liquid.
- 5. preparation method as claimed in claim 2 or claim 3, it is characterized in that ginseng extract medicinal extract described in step 3) is relatively close Spend for 1.05-1.25.
- 6. preparation method as claimed in claim 2 or claim 3, it is characterized in that the concentration of ginseng extract solution described in step 4) is 1-60%.
- 7. preparation method as claimed in claim 2 or claim 3, it is characterized in that also including soaking honeysuckle, Folium Forsythia in step 5) The 30-60min in described ginseng extract solution, then carry out described drying and processing.
- 8. preparation method as claimed in claim 2 or claim 3, it is characterized in that drying and processing temperature is 60-90 DEG C in step 5).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410613353.9A CN104644759B (en) | 2013-11-22 | 2014-11-04 | A kind of health protection tea for preventing or/and treating influenza and preparation method thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013105899974 | 2013-11-22 | ||
| CN201310589997 | 2013-11-22 | ||
| CN201410613353.9A CN104644759B (en) | 2013-11-22 | 2014-11-04 | A kind of health protection tea for preventing or/and treating influenza and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104644759A CN104644759A (en) | 2015-05-27 |
| CN104644759B true CN104644759B (en) | 2018-01-09 |
Family
ID=53236728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410613353.9A Active CN104644759B (en) | 2013-11-22 | 2014-11-04 | A kind of health protection tea for preventing or/and treating influenza and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104644759B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106509198A (en) * | 2015-09-15 | 2017-03-22 | 郭进军 | Formula preparation technology and usage of health-care tea |
| CN106615431B (en) * | 2016-12-08 | 2020-11-13 | 山东植益源健康科技有限公司 | Jerusalem artichoke tea tablets and preparation method thereof |
| CN114177220A (en) * | 2020-09-14 | 2022-03-15 | 富力 | The composition of forsythia and its antiviral and other medicinal uses |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152261A (en) * | 2007-09-04 | 2008-04-02 | 北京理工大学 | Application of phenylethanol glycosides and lignin glycosides components in forsythia (fruit or leaf) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010083662A (en) * | 2000-02-17 | 2001-09-01 | 손남율 | Antiviral and Anticancer Agents |
-
2014
- 2014-11-04 CN CN201410613353.9A patent/CN104644759B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152261A (en) * | 2007-09-04 | 2008-04-02 | 北京理工大学 | Application of phenylethanol glycosides and lignin glycosides components in forsythia (fruit or leaf) |
Non-Patent Citations (2)
| Title |
|---|
| 中药抗流感病毒的最新进展;孙平华;《中医药学刊》;20060430;第24卷(第4期);第733-735页，尤其是第734页左栏第3段、右栏最后1段 * |
| 金银花、连翘配伍提取物体外抗甲型流感病毒FM1株的实验研究;潘曌曌等;《甘肃中医学院学报》;20070430;第24卷(第2期);第5-8页，尤其是摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104644759A (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102178844B (en) | Oral Chinese medicine preparation for treating gum swelling and pain and preparation method thereof | |
| CN103719498A (en) | Immunity-enhancing sealwort health-care tea and preparation method thereof | |
| CN102846852A (en) | Composite for lowering blood fat and regulating immunity | |
| CN103719491B (en) | A kind of sealwort invigorating the spleen moistening lung health protection tea and preparation method thereof | |
| CN104208581A (en) | Schisandra chinensis health care oral liquid capable of preventing alcoholic liver and preparation method thereof | |
| CN104644759B (en) | A kind of health protection tea for preventing or/and treating influenza and preparation method thereof | |
| CN104645107A (en) | Traditional Chinese medicine composition, and preparation method and application thereof | |
| CN108523121A (en) | A kind of functional food and preparation method thereof of anti-haze clearing lung-heat | |
| CN101628108A (en) | Traditional Chinese medicinal granules for treating wind-cold evil and preparation method thereof | |
| CN108813501A (en) | With the relieving cough and reducing sputum health honey paste relievingd asthma and adjust function of human body of clearing heat and moistening lung | |
| CN109394809A (en) | A kind of Chinese medicine composition and its preparation method and application improving immunity | |
| CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
| CN101856415A (en) | Chinese Herbal Medicine Oral Liquid for Treating Chicken Respiratory Tract Infectious Diseases | |
| CN103520318A (en) | Traditional Chinese medicine composition of enhancing immune function and preparation method of composition | |
| KR101413283B1 (en) | The method for manufacturing panax ginseng composite by using the complex extract for the enhancement of immunity, and the panax ginseng composite made by the method | |
| CN105943617A (en) | Application of whole hemp extract in preparation of anti-hepatitis drugs | |
| KR100609643B1 (en) | Herbal medicine composition for the treatment of dermatitis and a method of manufacturing the same | |
| CN104940628A (en) | Traditional Chinese medicine composition capable of preventing flu and preparation method | |
| CN104474404A (en) | Compound suppositorycontrollinginfectionof immunodeficiency patient | |
| CN108260682A (en) | A kind of hypoglycemic, reducing blood lipid and the health protection tea of blood pressure lowering | |
| CN106309758A (en) | Pharmaceutical composition with efficacy of resisting gastrointestinal cancer | |
| CN106214844A (en) | A kind of compositions with fat-reducing and immunoregulation effect and preparation method thereof | |
| CN105998196A (en) | Blood sugar decreasing healthcare pharmaceutical composition prepared from fiveleaf gynostemma herb | |
| CN119033108B (en) | Medicinal and edible composition with immunity improving function and preparation method and application thereof | |
| CN116849357B (en) | Medicinal and edible composition with liver protection function and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |